Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1986 4
1989 2
1990 2
1991 2
1992 3
1993 3
1994 9
1995 6
1996 6
1997 6
1998 9
1999 6
2000 7
2001 9
2002 18
2003 11
2004 18
2005 11
2006 21
2007 26
2008 18
2009 31
2010 46
2011 42
2012 47
2013 55
2014 40
2015 40
2016 58
2017 42
2018 42
2019 54
2020 56
2021 64
2022 59
2023 58
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

859 results

Results by year

Filters applied: . Clear all
Page 1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. Jellinger PS, et al. Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL. Endocr Pract. 2017. PMID: 28437620
RESULTS: The Executive Summary of this document contains 87 recommendations of which 45 are Grade A (51.7%), 18 are Grade B (20.7%), 15 are Grade C (17.2%), and 9 (10.3%) are Grade D. ...CONCLUSION: This CPG is a practical tool that endocrinologists, other health care …
RESULTS: The Executive Summary of this document contains 87 recommendations of which 45 are Grade A (51.7%), 18 are Grade B (20.7%), …
British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.
Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM. Hurst JR, et al. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. J Allergy Clin Immunol Pract. 2017. PMID: 28351785 Free article. Review.
A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung disease (GLILD). ...There was no consensus on whether expectant management following optimization of immunoglobulin therapy was acceptab …
A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung dis …
Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment.
Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, Zhang S, Wang L, Yang Z, Sun K, Li H, Brown MD, Islami F, Bray F, Jemal A, He J. Chen W, et al. Lancet Glob Health. 2019 Feb;7(2):e257-e269. doi: 10.1016/S2214-109X(18)30488-1. Lancet Glob Health. 2019. PMID: 30683243 Free article.
FINDINGS: About 1 036 004 cancer deaths (45.2% of all cancer deaths [95% CI 44.0-46.4]) in China in 2014 in adults aged 20 years or older were attributable to 23 evaluated risk factors. The PAF was higher in men (51.2% [95% CI 50.0-52.4]) than in women (34.9% [33.6-36.2]), …
FINDINGS: About 1 036 004 cancer deaths (45.2% of all cancer deaths [95% CI 44.0-46.4]) in China in 2014 in adults aged 20 years or older we …
Pregnancy in primary immunodeficiency diseases: The PREPI study.
Mallart E, Françoise U, Driessen M, Blanche S, Lortholary O, Lefort A, Caseris M, Fischer A, Mahlaoui N, Charlier C; PREPI study group. Mallart E, et al. J Allergy Clin Immunol. 2023 Sep;152(3):760-770. doi: 10.1016/j.jaci.2023.05.006. Epub 2023 May 18. J Allergy Clin Immunol. 2023. PMID: 37210041
BACKGROUND: Primary immunodeficiencies (PID) are a heterogeneous group of rare inborn immunity defects. ...We analyzed PID features, pregnancy course and outcome, and neonatal features (NCT04581460). RESULTS: We studied 93 women with PID (27 combined immunodeficiencies …
BACKGROUND: Primary immunodeficiencies (PID) are a heterogeneous group of rare inborn immunity defects. ...We analyzed PID features, …
Hypertension in HIV: Management and Treatment.
Ucciferri C, Falasca K, Vecchiet J. Ucciferri C, et al. AIDS Rev. 2017 Oct-Dec;19(4):198-211. AIDS Rev. 2017. PMID: 28534890 Review.
It is estimated that in 2013, hypertension was responsible for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Accordingly, management of hypertension and its long-term complications in HIV-infected subjects is a significant component of routin …
It is estimated that in 2013, hypertension was responsible for at least 45% of deaths due to heart disease and 51% of deaths due to s …
Trends in TB and HIV care and treatment cascade, Kenya, 2008-2018.
Weyenga H, Onyango E, Katana AK, Pathmanathan I, Sidibe K, Shah NS, Ngugi EW, Waruingi RN, Ng Ang A L, De Cock KM. Weyenga H, et al. Int J Tuberc Lung Dis. 2022 Jul 1;26(7):623-628. doi: 10.5588/ijtld.21.0408. Int J Tuberc Lung Dis. 2022. PMID: 35768918
BACKGROUND: HIV infection is associated with high mortality among people with TB. Antiretroviral therapy (ART) reduces TB incidence and mortality among people living with HIV (PLHIV). ...Concerted efforts are needed to address case detection and gaps in quality of TB ca …
BACKGROUND: HIV infection is associated with high mortality among people with TB. Antiretroviral therapy (ART) reduces TB incidence a …
Tecovirimat for the treatment of severe Mpox in Germany.
Hermanussen L, Brehm TT, Wolf T, Boesecke C, Schlabe S, Borgans F, Monin MB, Jensen BO, Windhaber S, Scholten S, Jordan S, Lütgehetmann M, Wiesch JSZ, Addo MM, Mikolajewska A, Niebank M, Schmiedel S. Hermanussen L, et al. Infection. 2023 Oct;51(5):1563-1568. doi: 10.1007/s15010-023-02049-0. Epub 2023 Jun 5. Infection. 2023. PMID: 37273167 Free PMC article.
Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. ...
Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed cli …
The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema.
Araújo-Simões J, Boanova AGP, Constantino-Silva RN, Fragnan NTML, Pinto JA, Minafra FG, Gonçalves RF, Valle SRD, Alonso MLO, Dortas SD, Goudouris ES, Rêgo-Silva AM, Marques MM, Serpa FS, Chong-Neto HJ, Nelson RF, Mansour E, Moreira IF, Moreno AS, Arruda LK, Roxo Junior P, Ferriani MPL, Silva J, Ferreira JFS, Giavina-Bianchi P, Takejima PM, Ensina LF, Campos RA, Toledo E, Pesquero JB, Palma SMU, Veronez CL, Grumach AS. Araújo-Simões J, et al. Int Arch Allergy Immunol. 2021;182(7):585-591. doi: 10.1159/000512944. Epub 2021 Jan 28. Int Arch Allergy Immunol. 2021. PMID: 33508850
On-demand therapy (35/80) was prescribed: icatibant in 7/35, fresh frozen plasma in 16/35, C1-INH plasma-derived in 11/35, and tranexamic acid in 12/35 patients. ...Educational programs should address pediatricians to reduce late diagnosis and tailored child therapy …
On-demand therapy (35/80) was prescribed: icatibant in 7/35, fresh frozen plasma in 16/35, C1-INH plasma-derived in 11/35, and tranex …
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice.
Canetti D, Galli L, Lolatto R, Nozza S, Spagnuolo V, Muccini C, Trentacapilli B, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Gianotti N. Canetti D, et al. Drug Des Devel Ther. 2023 Dec 8;17:3697-3706. doi: 10.2147/DDDT.S437043. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 38090027 Free PMC article.
Discontinuation occurred in 15% after a median time of 13.5 months of follow-up, with an incidence rate of 5.67 per 1000 PMFU, and a probability at 24-30 months of 11.9%-15.3%, respectively. Main discontinuation reasons were simplification (51.3%) and toxicity (21.8%, invo …
Discontinuation occurred in 15% after a median time of 13.5 months of follow-up, with an incidence rate of 5.67 per 1000 PMFU, and a probabi …
859 results